Divi’s Labs (DIVI), in addition to having a robust base business, is enhancing its product offerings in the generic API space – at least sixteen molecules are under various phases of development and ...

Divi's Laboratories, India's largest API (Active Pharmaceutical Ingredient) manufacturer, sits amid a changing landscape within the global pharmaceutical universe. The growth levers for Divi’s are ...

The pharmaceutical industry has been traditionally slow in embracing new technologies, but Divi’s Laboratories is showing the way forward. Recently, this Hyderabad-based firm zeroed in on Juniper ...

Nov 7 (Reuters) - Indian drugmaker Divi's Laboratories (DIVI.NS), opens new tab reported second-quarter profit above analysts' estimates on Friday, helped by its business that focuses on customised ...

HYDERABAD, Feb 3 (Reuters) - India's Divi's Laboratories (DIVI.NS), opens new tab reported a better-than-expected quarterly profit on Monday, aided by strong performance of its business that focuses ...

Divi's Labs reported its Q1 results on August 3. Pharma company Divi's Laboratories announced plans to foray into peptide fragment molecules, advancing from the peptide building blocks it currently ...

FDA inspectors say employees at a Divi's Laboratories plant in India repeatedly refused to give them the records needed to determine whether its APIs were adulterated. The FDA, which last month banned ...